2019 Webinar: Liquid Biopsy in Hepatocellular Carcinoma: Applications in Surveillance and Prediction of Treatment Response-Liquid Biopsy in Hepatocellular Carcinoma: Applications in Surveillance and Prediction of Treatment Response

Liquid Biopsy in Hepatocellular Carcinoma: Applications in Surveillance and Prediction of Treatment Response

Video Transcription

Video Summary

The webinar discussed the use of liquid biopsy, specifically circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs), in hepatocellular carcinoma (HCC). The presenters discussed the potential applications of liquid biopsy, such as early detection of HCC, monitoring treatment response, and predicting prognosis. They emphasized the advantages of liquid biopsy, including its non-invasive nature and ability to capture real-time changes in tumor composition. Dr. Kiesel presented his work on ctDNA and the use of DNA methylation as a biomarker for early detection of HCC. He highlighted the high sensitivity and specificity of DNA methylation markers and their potential for use in clinical practice. Dr. Yang discussed the use of CTCs as a biomarker for HCC. He presented data showing the association of CTCs with disease progression and overall survival in HCC patients. However, he also noted the limitations of CTC detection, such as its lower sensitivity for smaller tumors. The presenters concluded that liquid biopsy has great potential for improving the diagnosis and management of HCC. However, further research and validation studies are needed before it can be implemented in routine clinical practice.

Asset Caption

Presenter: John Kisiel, MD; Lewis R. Roberts, MBChB, PhD, FAASLD; Augusto Villanueva, MD, PhD and Ju Dong Yang, MD, MS
Moderator: Augusto Villanueva, MD, PhD

Keywords

liquid biopsy

ctDNA

CTCs

hepatocellular carcinoma

early detection

treatment response

DNA methylation

biomarker

sensitivity

clinical practice